uniQure N.V. has converted a year of Food and Drug Administration whiplash into a live review file. On September second the Dutch gene-therapy company submitted a biologics license application for ifezuntirgene inilparvovec, the striatal huntingtin-silencing candidate known as AMT-130, seeking accelerated approval in Huntington disease, and filed a parallel marketing application in the United Kingdom. The same three-year early-stage package that the agency set aside as primary evidence in November, and again after a January Type A meeting, is now the stated basis of the file, after June Type B minutes called that package a reasonable foundation for an accelerated-approval submission. The equity is no longer debating whether a filing happens. It is debating whether a small, externally controlled dataset survives the sixty-day filing check and a subsequent review.
The commercial setup is a one-time neurosurgical gene therapy aimed at a disease with no approved disease-modifying treatment and a diagnosed population of about seventy-five thousand people across the United States, Europe, and the United Kingdom. Cash, cash equivalents, and current investment securities stood at $810 million at mid-year after a June follow-on. That offering brought $259 million of gross proceeds and, on management's stated runway, funds a launch and a confirmatory trial into the next decade. The offset sits on the liability side. A royalty-financing obligation tied to the lowest HEMGENIX royalty tier still carries nearly half a billion in carrying value, so enterprise value is not cash-net of a clean biotech balance sheet.
The second-quarter print is not the story. License revenue stayed in the mid-single-digit millions, research spending eased, and selling costs rose as the company hired for a possible Huntington launch. Net loss widened to $81 million mostly because foreign-currency and pre-funded-warrant marks flipped against the company, not because the operating burn broke. Four-year follow-up on twenty-four treated patients remains outstanding as of this publication date, and the confirmatory design is still being negotiated. Does the agency accept an externally controlled file for the first Huntington disease-modifying claim, or does the November reversal reassert itself at filing review?